Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Dr Lamy and Dr Gonzalez-Rodriguez.
Cummings SR, Ferrari S, Brown JP, Wang AT. Cummings SR, et al. J Bone Miner Res. 2018 Mar;33(3):548. doi: 10.1002/jbmr.3403. J Bone Miner Res. 2018. PMID: 29419889 Free article. No abstract available.
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. Eastell R, et al. Among authors: wang a. J Bone Miner Res. 2011 Mar;26(3):530-7. doi: 10.1002/jbmr.251. J Bone Miner Res. 2011. PMID: 20839290 Free article. Clinical Trial.
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A. Bilezikian JP, et al. Among authors: wang at. Osteoporos Int. 2019 Sep;30(9):1855-1864. doi: 10.1007/s00198-019-05020-8. Epub 2019 Jun 14. Osteoporos Int. 2019. PMID: 31201481 Free PMC article. Clinical Trial.
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, Törring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C, Lewiecki EM. Ferrari S, et al. Among authors: wang a. Osteoporos Int. 2015 Dec;26(12):2763-71. doi: 10.1007/s00198-015-3179-x. Epub 2015 Jun 12. Osteoporos Int. 2015. PMID: 26068295 Free PMC article. Clinical Trial.
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.
Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, Muñoz Torres M, Wang A, Bone HG. Kendler DL, et al. Among authors: wang a. Osteoporos Int. 2019 Jan;30(1):71-78. doi: 10.1007/s00198-018-4687-2. Epub 2018 Sep 22. Osteoporos Int. 2019. PMID: 30244369 Free PMC article. Clinical Trial.
Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, de Gregόrio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM. Ferrari S, et al. Among authors: wang a. J Bone Miner Res. 2019 Jun;34(6):1033-1040. doi: 10.1002/jbmr.3722. Epub 2019 May 29. J Bone Miner Res. 2019. PMID: 30919997 Free PMC article. Clinical Trial.
16,285 results
You have reached the last available page of results. Please see the User Guide for more information.